Neeta B Amin

6PUBLICATIONS
14CO-AUTHORS
PharmacogenomicsWastewater treatment processesPredictive and prognostic markersCheminformatics and quantitative structure-activity relationshipsBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 29, 2026
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.

|Sep 25, 2025
Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor.

Manoli Vourvahis, Arthur J Bergman, Adam G Ogden

|Nov 20, 2024
Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.

Jim H Hughes, Neeta B Amin, Jessica Wojciechowski

|Apr 06, 2022
Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.

Tim F Ryder, Arthur Bergman, Amanda King-Ahmad

|Mar 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.

Neeta B Amin, Amanda Darekar, Quentin M Anstee

|Nov 29, 2019
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.

Neeta B Amin, Santos Carvajal-Gonzalez, Julie Purkal

Pageof 1

Frequent Collaborators

2 joint publications

Amit S Kalgutkar

2 joint publications

Jim Hughes

1 joint publications

Santos Carvajal-Gonzalez

1 joint publications

Julie Purkal